Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 12/13 Goblet PC patients had Stage IV metastatic (M1) cancer

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Dec 06, 2022 4:18pm

106 Views

Post# 35154429

RE:RE:RE:RE:12/13 Goblet PC patients had Stage IV metastatic (M1) cancer

Thank you Noteable. Got a bit confused as the non-metatstatic patient should not be classified as Stage IV. I could very well be wrong in that. Nevertheless we have a metastatic pancreatic cancer patient with a CR.

I was trying to winnow out of the essence of GOBLET. A metastatic pancreatic cancer patient with a CR.

Cheers

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China